newsfilter
← Latest News
GlobeNewswire·

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability Additional preclinical